Medtech regulatory dynamics 2020: 6 big regulatory updates and takeaways for medtech teams

Since the identification of the novel coronavirus SARS-CoV-2 in December 2019, the disease has spread to nearly every country and territory on the planet, and governments and authorities have all implemented some form of infection containment measures, whether through travel restrictions, business closures, or social isolation, in a bid to slow down and control the pace of infection. Lockdowns began being enforced in China in January 2020, effectively closing most manufacturing operations across the country, and other regions followed suit as the virus spread, impacting manufacturing hubs in Southeast Asia, the US, Eastern Europe, Ireland, Mexico, and Central America.

In addition to having forced some unprecedented shifts among both healthcare and non-healthcare manufacturers, the pandemic has caused countries and companies to reconsider their previous manufacturing policies, and many are now looking to diversify their manufacturing and supply chain networks, whether by onshoring manufacturing operations or spreading them across more countries to avoid an overreliance on any one location.

In this e-book, we identify how the COVID-19 pandemic is disrupting manufacturing among both healthcare and non-healthcare companies, outline efforts and initiatives to improve the resilience of manufacturing networks in the face of global system shocks, and highlight anticipated long-term impacts from ongoing and proposed manufacturing shifts in the MedTech space.